Document ID: chunk:federal_register_of_legislation:F2025C00183:clause:1_73429
Version: federal_register_of_legislation:F2025C00183
Segment Type: clause
Provision Reference: sch 1 cl 73429
Character Range: 374254–375219

73429              Genetic testing (including characterisation of single nucleotide variants, structural variants, fusions and copy number alterations) in a gene panel, requested by a specialist or consultant physician, for a patient with clinical or laboratory evidence of a glioma, glioneuronal tumour or glioblastoma, to aid diagnosis and classification of the relevant tumour, including assessments of at least the following kinds:                                                                                                                                     887.90
                   (a) IDH1, IDH2—variant testing;
                   (b) 1p/19q—co‑deletion assessment;
                   (c) H3F3A—variant status;
                   (d) TERT—promoter variant status;
                   (e) EGFR—amplification;
                   (f) CDKN2A/B—deletion;
                   (g) BRAF—variants
                   Applicable to one test per diagnostic episode